Zura Bio to Present at Two Miami Healthcare Conferences
Event summary
- Zura Bio management to participate in Leerink Global Healthcare Conference on March 10, 2026, with a fireside chat at 2:20 p.m. ET.
- Company will also attend Jefferies Biotech on the Beach Summit on March 11, 2026, for investor meetings.
- Live webcast of Leerink fireside chat available on Zura Bio's Investors section, with replay accessible for 30 days.
- Zura Bio's pipeline includes lead candidate tibulizumab (ZB-106) in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis.
The big picture
Zura Bio's participation in high-profile investor conferences comes at a critical juncture as it advances its lead clinical candidates. The company is positioning itself in a competitive immunology space, where differentiation through novel dual-pathway antibodies could drive long-term success. The upcoming investor meetings will be key in gauging market appetite for its pipeline.
What we're watching
- Pipeline Progress
- How Phase 2 trial results for tibulizumab will impact Zura Bio's valuation and investor confidence.
- Investor Sentiment
- Whether management can effectively communicate the company's strategic vision during investor meetings.
- Competitive Positioning
- The pace at which Zura Bio can differentiate itself in the crowded autoimmune and inflammatory disease market.
Related topics